Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 12/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 12/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 11/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872291 | 0.81 | TSHR (0.41) | SLC7A5TSHR | |
| SCHEMBL2030960 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29957288 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL398123 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL12843923 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL398124 | 0.80 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7268427 | 0.79 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Hydrochloric Acid SCHEMBL1536307 | 0.78 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8715906 | 0.78 | SLC7A5 (0.46) | SLC7A5SLC1A3SLC1A2SLC1A1MEN1 | |
| SCHEMBL9730337 | 0.77 | TSHR (0.35) | SLC7A5CYP2D6CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | SLC7A5 66/4885SLC1A3 184/4885SLC1A2 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.